TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00652275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSP3 Long Synthetic Peptide 30 micrograms of MSP3 LSP
Description: 189 children will receive 3 doses of experimental vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Verorab vaccine
Description: 189 volunteers will receive Verorab vaccine, 0.5 Ml at day 0, 28 and 56.
Study: NCT03291132

Intervention type: OTHER
Group type: OTHER
Intervention: training camp
Description: The Smoke-free teens will join a 2-Day-1-Night training camp in July or August. The camp will cover a wide range of indoor, outdoor, adventure-based, experiential learning activities. Besides, the teens will be equipped with the knowledge on smoking hazards, tobacco control and smoking cessation. The teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model: By the end of the training camp, the teens should be confident and competent in delivering the brief smoking cessation intervention to smokers. The teens will then break down into groups to organize smoke-free programmes in their schools or in the community.~All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the training camp (T2), and 3 (T3) and 6 months later (T4). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 (T3) and 6 (T4) months.
Study: NCT05031143

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Suprachoroidal Triamcinolone acetonide injection for serous retinal detachment in VKH disease
Description: Suprachoroidal steroid injection for management of serous retinal detachment in VKH disease
Study: NCT02622035

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of information
Description: Information about fruit and vegetable feeding for children framed in gain vs. loss manner

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of information
Description: Information about fruit and vegetable feeding for children framed in gain vs. loss manner

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of information
Description: Information about fruit and vegetable feeding for children framed in gain vs. loss manner

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provision of information
Description: Information about fruit and vegetable feeding for children framed in gain vs. loss manner

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion induction
Description: Film clip designed to induce anger or fear

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion induction
Description: Film clip designed to induce anger or fear

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion induction
Description: Film clip designed to induce anger or fear

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emotion induction
Description: Film clip designed to induce anger or fear

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visual perceptual load
Description: visual and interactivity-based load of virtual reality buffet environment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visual perceptual load
Description: visual and interactivity-based load of virtual reality buffet environment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: visual perceptual load
Description: visual and interactivity-based load of virtual reality buffet environment
Study: NCT01732536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S8 Sinus Implant
Description: In-office bilateral placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham procedure
Description: In-office bilateral sham procedure
Study: NCT03150017

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SPIRE
Description: Online pain management programme.
Study: NCT02758223

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TCM allogeneic humane central memory T cells, cryopreserved
Description: Experimental: TCM allogeneic humane central memory T cells, cryopreserved Solution for injection (intravenous use) up to 65\*10\^4 TCM /kg body weight patient will receive investigational product 3 times (Day 30, Day 60, Day 90 after alloHSCT)
Study: NCT00795964

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Randomized application of intraoperative tidal volume
Description: intraoperative mechanical ventilation with 6 ml/kg predicted body weight
Study: NCT04092582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTPS9579A
Description: MTPS9579A IV infusion will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks through Week 46.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching MTPS9579A will be administered at the randomization visit (Week 2), Week 6, and every 4 weeks thereafter through Week 46.
Study: NCT00795964

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Randomized application of intraoperative tidal volume
Description: intraoperative mechanical ventilation with 12 ml/kg predicted body weight
Study: NCT03585699

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy Guided Spinal Biopsy
Description: Spinal biopsy done via Transpedicular approach with an 8-gauge T-Lok™ bone marrow biopsy needle under fluoroscopic guidance.~Samples collected were sent to laboratories for histopathological examination (HPE), culture and sensitivity (bacteriology, mycology and acid-fast bacilli), staining (Gram and Ziehl-Neelsen) and polymerase chain reaction (PCR) test for Mycobacterium tuberculosis.
Study: NCT02363608

Intervention type: BEHAVIORAL
Intervention: baseline and post assessment
Description: The baseline and post assessment will include the Professional Quality of Life Scale (ProQOL R-IV) (Stamm, 1997-2005) and qualitative questions.
Study: NCT02362984

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo of DLBS1033 will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DLBS1033
Description: DLBS1033 enteric-coated tablets will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
Study: NCT00690274

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BF2.649
Description: up to 20mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: up to 20mg per day
Study: NCT05638178

Intervention type: OTHER
Intervention: No intervention
Description: No intervention, cohort study.

Intervention type: OTHER
Intervention: No intervention
Description: No intervention, cohort study.
Study: NCT00896246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Klean-Prep®
Description: Four litres of solution administered orally as a divided dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moviprep®
Description: Two litres of solution administered orally as a divided dose
Study: NCT01244269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate 10mg tablets will be overencapsulated in gelatin capsules for blinding. Subjects will take 1 capsule three times daily for a total of 7 doses.
Study: NCT01732536

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Mometasone furoate nasal spray
Description: Two sprays in each nostril once daily, totaling 200 mcg of mometasone furoate throughout Day 90
Study: NCT01244269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Methylphenidate 20mg three times daily for a total of 7 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 10
Description: Blind gelatin capsule three times daily for a total of 7 doses.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 20
Description: Blind gelatin capsule three times daily for a total of 7 doses
Study: NCT03725930

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clonidine
Description: clonidine intranasal premedication in preschool infants

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intranasal premedication
Study: NCT01472328

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: HBO therapy
Description: Effect of 2 hrs HBO therapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
Study: NCT03585699

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CT guided Spinal Biopsy
Description: Spinal biopsy done via Transpedicular approach with an 8-gauge T-Lok™ bone marrow biopsy needle under CT guidance.~Samples collected were sent to laboratories for histopathological examination (HPE), culture and sensitivity (bacteriology, mycology and acid-fast bacilli), staining (Gram and Ziehl-Neelsen) and polymerase chain reaction (PCR) test for Mycobacterium tuberculosis.
Study: NCT01658462

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: 75 mg/m2 IV Day 1 / 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: 75 mg/m2 IV Day 1 / 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: 200 mg x 2 per os daily from D2\*~\*No Nintedanib on days when docetaxel is administered

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel: increase of the dose
Description: Dose can be increased to 100 mg/m² secondarily at cycle 2 on the initiative of the investigator
Study: NCT01776892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Collegenase injection
Description: Collagenase clostridium histolyticum will be used to treat participants in this arm of the study. Affected cords will be treated with 1-3 collagenase injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections.~Metacarpophalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.25ml of sterile diluent. Proximal interphalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.20ml of sterile diluent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Collegenase injection
Description: Collagenase clostridium histolyticum will be used to treat participants in this arm of the study. Affected cords will be treated with 1-3 collagenase injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections.~Metacarpophalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.25ml of sterile diluent. Proximal interphalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.20ml of sterile diluent.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Needle aponeurotomy
Description: Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needle aponeurotomy
Description: Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained.
Study: NCT03570073

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual vitrification
Description: Two oocytes will be frozen by vitrification. At thawing, the degree of rehydration objectified by the measurement of oocyte surfaces and the appearance of potential lysis will be studied thanks to culture in the embryoscope.
Study: NCT00967733

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flaxseed oil-Olive oil
Description: 2 or 4 gr per day alpha-linolenic acid pill and olive oil used for cooking

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil-olive oil
Description: 1 gr olive oil pill and olive oil used for cooking

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Flaxseed oil-sunflower oil
Description: 2 or 4 gr per day alpha linolenic acid pill and sunflower oil used for cooking

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Olive oil-sunflower oil
Description: 1 gr olive oil pill and sunflower oil used for cooking
Study: NCT01769469

Intervention type: DRUG
Intervention: FTC/TDF (Truvada®)
Description: There are no interventions for this study except that subjects will be administered FTC/TDF (Truvada®) will be administered as part of ATN 110 and ATN 113.
Study: NCT00546286

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dorzolamide hydrochloride (+) timolol maleate
Description: Combination treatment of dorzolamide HCl (2%)/ timolol maleate (0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.~For patients who achieve target IOP at 6 weeks, dorzolamide/timolol is continued for another 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: dorzolamide HCl/timolol maleate + prostaglandin
Description: Combination treatment of dorzolamide HCl (2%)/timolol maleate(0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.~For patients not achieving target IOP at 6 weeks, a prostaglandin is added for another 6 weeks.
Study: NCT01760759

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cell phone reminders
Description: Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cell phone reminders
Description: Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: contingency management for adherence
Description: Patients will receive reinforcement in the form of vouchers for each video that they send in indicating adherence at the appropriate time.
Study: NCT02615067

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 99mTc-MIP-1404 Injection
Description: A single dose of 20 (±3) mCi intravenous (IV) injection of 99mTc-MIP-1404.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Whole-Body Planar and pelvic SPECT/CT scan
Description: A whole-body planar and pelvic SPECT/CT scan will be obtained 3-6 hours after injection of 99mTc-MIP-1404.
Study: NCT04462536

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vehicle only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerinetide
Description: Single intravenous infusion of nerinetide 2.6 mg/kg (up to a maximum dose of 270 mg) over 10 ± 1 minutes
Study: NCT01090219

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: two different meshes in the repair of inguinal hernias
Description: A Lichtenstein tension-free hernia repair was accomplished by emplacing Heavy-weight versus low-weight polypropylene meshes for repair of incisional hernia, marked next to the lips with six titanium clips (LT200)
Study: NCT04469816

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Check-Up 4 Health
Description: A parent-training intervention to improve child health, school readiness and manage obesity.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Services as Usual
Description: Services/Treatment as usual.
Study: NCT02437487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SER-109
Description: SER 109 is a rationally designed ecology of bacterial spores enriched from stool donations obtained from healthy, screened donors.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be identical to the investigator product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
Study: NCT02409056

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Workplace-tailored CDSMP
Description: This is the CDSMP program which has been modified to fit the unique characteristics of the workplace and will be offered in worksites.
Study: NCT01732536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray
Description: Two sprays in each nostril once daily, totaling 200 mcg of mometasone furoate throughout Day 90
Study: NCT01231789

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: RIPC
Description: RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
Study: NCT02409056

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Disease Self-Management Program
Description: This is the standard CDSMP which has been implemented in community settings.
Study: NCT00651612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution
Description: Brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution 1 drop instilled in each eye two times daily (morning and evening)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent brimonidine 0.2% and 0.5% timolol
Description: Brimonidine 0.2%, 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and timolol 0.5% timolol, 1 drop instilled in each eye twice daily (morning and evening) and vehicle of brimonidine combination ophthalmic solution 1 drop instilled in each eye (morning, afternoon and/or evening)
Study: NCT00505752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS900672-Enriched 50 microgram (mcg)
Description: Single injection of AS900672-Enriched (hyperglycosylated recombinant human follicle stimulating hormone \[r-hFSH\]), 50 mcg will be administered subcutaneously on Stimulation Day 1 (S1). Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS900672-Enriched 100 mcg
Description: Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 100 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
Study: NCT03433690

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HIIT
Description: High Intensity Interval Training for twelve weeks

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate training
Description: Moderate training for twelve weeks
Study: NCT00505752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AS900672-Enriched 150 mcg
Description: Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 150 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin alfa 150 international unit (IU)
Description: Follitropin alfa (Gonal-f®) 150 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 21 (S21) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 50, 100 and 150 mcg will also receive daily dose of follitropin alfa 150 IU subcutaneously from Stimulation Day 6 (S6) up to S21. Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
Study: NCT01231789

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: sham RIPC
Description: Patients had a deflated cuff placed on the right upper arm for 30 min without any inflation procedure.
Study: NCT00937495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: 400 mg given PO
Study: NCT01472328

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Hyperbaric room air
Description: Effect of 2 hrs hyperbaric room air on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
Study: NCT00735917

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saracatinib
Description: Given PO
Study: NCT00505752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Follitropin alfa 150 international unit (IU)
Description: Follitropin alfa (Gonal-f®) 150 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 21 (S21) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 50, 100 and 150 mcg will also receive daily dose of follitropin alfa 150 IU subcutaneously from Stimulation Day 6 (S6) up to S21. Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
Study: NCT00735917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Optional correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Optional correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Optional correlative studies
Study: NCT00548418

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Study: NCT00735917

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Optional correlative studies
Study: NCT00937495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: 1.3 mg/m\^2 given IV
Study: NCT04587037

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fascia lata allograft
Description: underwent superior capsule reconstruction using fascia lata allograft

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: human dermal allograft
Description: underwent superior capsule reconstruction using human dermal allograft
Study: NCT03667404

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resistant maltodextrin
Description: Resistant maltodextrin powder

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: maltodextrin
Description: maltodextrin powder
Study: NCT02135744

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Bundle tool
Description: Tool consists of 1. screening measures to identify the presence of various risk factors for COPD exacerbations and 2. Educational components for the disease of COPD.